Results 121 to 130 of about 76,979 (321)

Risk of Serious Infections in Patients Treated With Biologic or Targeted‐synthetic Disease Modifying Antirheumatic Drugs in Qatar

Immunity, Inflammation and Disease, Volume 13, Issue 4, April 2025.
This study investigates the risk of serious infections (SIs) in patients treated with biologic or targeted‐synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) in Qatar. Out of 1092 patients, 86 (7.9%) experienced SIs, with adalimumab and infliximab associated with higher SI rates.
Sreethish Sasi, Hamad Abdel Hadi, Masautso Chaponda, Reem El Ajez, Mohamed Ataelmanan, Sief Khasawneh, Hind Saqallah, Maisa Ali, Nabeel Abdulla, Javed Iqbal, Ali S. Omrani, Muna Al Maslamani, Abdullatif Al‐Khal   +12 more
wiley   +1 more source

Should Pneumococcal Serotype 3 Be Included in Serotype-Specific Immunoassays?

Vaccines, 2019
Since the introduction of the 13-valent pneumococcal conjugate vaccine, a number of studies have demonstrated the limited efficacy of the pneumococcal serotype 3 component of this vaccine. Evidence from seven countries (Denmark, France, Greece, Portugal,
Ezra Linley, Abigail Bell, Jenna F. Gritzfeld, Ray Borrow   +3 more
doaj   +1 more source

Vaccination dilemma on an evolving social network [PDF]

arXiv, 2019
Vaccination is crucial for the control of epidemics. Yet it is a social dilemma since non-vaccinators can benefit from the herd immunity created by the vaccinators. Thus the optimum vaccination level is not reached via voluntary vaccination at times.
arxiv  

Etiology of Acute Otitis Media and Characterization of Pneumococcal Isolates After Introduction of 13-Valent Pneumococcal Conjugate Vaccine in Japanese Children

The Pediatric Infectious Disease Journal, 2018
Background: Acute otitis media is a leading cause of childhood morbidity and antibiotic prescriptions. We examined etiologic changes in acute otitis media after introduction of 13-valent pneumococcal conjugate vaccine as routine immunization for Japanese
K. Ubukata, Miyuki Morozumi, Megumi Sakuma, Misako Takata, E. Mokuno, T. Tajima, S. Iwata   +6 more
semanticscholar   +1 more source

Beyond Childhood: Adult and Adolescent Sickle Cell Disease and Outcomes in Northern Ghana

eJHaem, Volume 6, Issue 2, April 2025.
ABSTRACT Background Adults and adolescents face different barriers to healthcare utilization compared to children. Objective To describe adult and adolescent sickle cell disease (SCD) and outcomes in northern Ghana. Methods This was a retrospective cohort study of SCD patients aged 13 years and above, admitted between January 1, 2021 and December 31 ...
Kwadwo Faka Gyan, Solomon Gyabaah, Eunice Agyeman Ahmed, Lesley Osei, Mohammed Najeeb Naabo, Michael Asiedu Owiredu, Yaw Obeng Opare‐Addo, Jessey Mahama Holu, Ohene Kwaku Opare‐Sem   +8 more
wiley   +1 more source

Dynamic Vaccination Game in a Heterogeneous Mixing Population [PDF]

, 2019
Opposition to vaccination has long been a non-negligible public health phenomenon resulted from people's varied perceptions toward vaccination (e.g., vaccine-phobia). This paper investigates the voluntary vaccination behavior of a heterogeneous population during an epidemic outbreak, where each individual makes its own vaccination decision to minimize ...
arxiv   +1 more source

TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth.

JCI Insight, 2017
Infection is the most common cause of mortality in early life, and immunization is the most promising biomedical intervention to reduce this burden. However, newborns fail to respond optimally to most vaccines.
David J. Dowling, S. V. van Haren, A. Scheid, Ilana Bergelson, Dhohyung Kim, Christy J Mancuso, W. Foppen, A. Ozonoff, L. Fresh, Terese B Theriot, A. Lackner, R. Fichorova, D. Smirnov, J. Vasilakos, Joe M Beaurline, M. Tomai, C. Midkiff, X. Alvarez, J. Blanchard, Margaret H. Gilbert, P. Aye, O. Levy   +21 more
semanticscholar   +1 more source

Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe [PDF]

, 2014
The global burden of pneumococcal diseases is high, with young children and adults ≥50 years of age at highest risk of infection. Two types of vaccine are available for the prevention of pneumococcal diseases caused by specific Streptococcus pneumoniae ...
Castiglia, Paolo Giuseppino
core   +1 more source

Global Authorship Representation in Otolaryngology Clinical Trials

Laryngoscope Investigative Otolaryngology, Volume 10, Issue 2, April 2025.
The clinical trial literature in the four most widely circulated OHNS journals is dominated by HIC authorship, with only marginal growth in LMIC contributions and no representation from LICs over the past two decades. This underrepresentation may impact the applicability of clinical guidelines in lower‐income regions.
Hong‐Ho Yang, Jeffrey D. Huynh, Clare Moffatt, Rolvix H. Patterson, Mary Jue Xu, Maie St. John   +5 more
wiley   +1 more source

Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine.

Clinical Infectious Diseases, 2016
BACKGROUND Antibiotic-nonsusceptible invasive pneumococcal disease (IPD) decreased substantially after the US introduction of the pediatric 7-valent pneumococcal conjugate vaccine (PCV7) in 2000.
S. Tomczyk, R. Lynfield, W. Schaffner, A. Reingold, L. Miller, S. Petit, C. Holtzman, S. Zansky, A. Thomas, J. Baumbach, L. Harrison, M. Farley, B. Beall, L. McGee, R. Gierke, Tracy Pondo, L. Kim   +16 more
semanticscholar   +1 more source